id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-302018-3rlya16w	Castells, Mariana C.	Drug allergy labeling and delabeling in the coronavirus disease 2019 era: What is important and what do we need to know	2020-05-22		.txt	text/plain	1939	97	38	The topics covered in this issue provide the necessary and updated knowledge for all allergists involved in labeling and delabeling procedures, aiming to broaden drug choices and treatment options for patients in this unknown world of COVID-19 pandemic and other disease states. Target populations for receiving a drug allergy label include the following: (1) children with approximately 70,000 visits to the emergency department reported annually for adverse drug events with penicillins, cephalosporins, and sulfamethoxazole-trimethoprim as the most frequent medications; and (2) hospitalized patients with cancer, of whom 23% have a label of antibiotic allergy. The authors concluded that current and future efforts should focus on preventing penicillin allergy labels that can carry over into adulthood, providing education and decision support in the electronic medical record, and testing low-risk drug administration strategies in low-risk patients. As more mechanisms of drug allergy are uncovered and new biomarkers become available, they can be incorporated into this flexible classification, guiding clinicians toward an optimal approach for patient labeling or delabeling, treatment, and management.	./cache/cord-302018-3rlya16w.txt	./txt/cord-302018-3rlya16w.txt